top of page

BIO International 2025: The new CEO of Sweden's Hansa Biopharma discusses potential uses of the company's IgG busting drug, imlifidase, including for kidney transplant and along with gene therapy

Jun 18, 2025

1 min read

Renée Aguiar-Lucander describes the kidney transplant population that the therapy currently has conditional approval with the EMA for, and how Hansa it trying to expand on it. Plus, development work in Guillain-Barré syndrome and gene therapy.

https://vimeo.com/1094459110?share=copy

Recent Posts

BIO-Europe: The FDA decision date for Hansa's IgG-inactivating therapy for kidney transplant patients is coming up on December 19th

BIO-Europe: The FDA decision date for Hansa's IgG-inactivating therapy for kidney transplant patients is coming up on December 19th

BIO-Europe 2026: Belgium based MRM Health believes its optimization method for microbiome treatments sets it apart - a key readout next year in UC will be a window into its potential

BIO-Europe 2026: Belgium based MRM Health believes its optimization method for microbiome treatments sets it apart - a key readout next year in UC will be a window into its potential

From Montreal: Congruence Therapeutics uses computational discovery to develop novel small molecule correctors and allosteric modulators - its lead program is for a high profile genetic obesity target

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

10x_Genomics_logo.svg.png

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

bottom of page